JP2007533625A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007533625A5 JP2007533625A5 JP2006527336A JP2006527336A JP2007533625A5 JP 2007533625 A5 JP2007533625 A5 JP 2007533625A5 JP 2006527336 A JP2006527336 A JP 2006527336A JP 2006527336 A JP2006527336 A JP 2006527336A JP 2007533625 A5 JP2007533625 A5 JP 2007533625A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- carboxy
- amino
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003277 amino group Chemical group 0.000 claims 26
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 20
- 239000003112 inhibitor Substances 0.000 claims 13
- -1 carboxy phenoxy group Chemical group 0.000 claims 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 9
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000004185 ester group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 150000003462 sulfoxides Chemical class 0.000 claims 8
- 125000004149 thio group Chemical group *S* 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- CYFLXLSBHQBMFT-UHFFFAOYSA-N sulfamoxole Chemical group O1C(C)=C(C)N=C1NS(=O)(=O)C1=CC=C(N)C=C1 CYFLXLSBHQBMFT-UHFFFAOYSA-N 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000005518 carboxamido group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 4
- 206010065687 Bone loss Diseases 0.000 claims 4
- 125000006725 C1-C10 alkenyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 210000000845 cartilage Anatomy 0.000 claims 4
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 4
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000003367 polycyclic group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical group C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 claims 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960003387 progesterone Drugs 0.000 claims 2
- 239000000186 progesterone Substances 0.000 claims 2
- 206010051728 Bone erosion Diseases 0.000 claims 1
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000009386 Experimental Arthritis Diseases 0.000 claims 1
- 239000004378 Glycyrrhizin Substances 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960000530 carbenoxolone Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960003720 enoxolone Drugs 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
- 125000002168 glycyrrhetinic acid group Chemical group 0.000 claims 1
- 239000001685 glycyrrhizic acid Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000001989 nasopharynx Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000000010 osteolytic effect Effects 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50471703P | 2003-09-22 | 2003-09-22 | |
| US60/504,717 | 2003-09-22 | ||
| PCT/EP2004/010582 WO2005027882A1 (en) | 2003-09-22 | 2004-09-21 | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007533625A JP2007533625A (ja) | 2007-11-22 |
| JP2007533625A5 true JP2007533625A5 (https=) | 2008-01-10 |
Family
ID=34375537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006527336A Pending JP2007533625A (ja) | 2003-09-22 | 2004-09-21 | 炎症性及び／又は免疫媒介性の骨量減少の予防及び治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20100087413A1 (https=) |
| EP (2) | EP1663185B1 (https=) |
| JP (1) | JP2007533625A (https=) |
| AT (1) | ATE416761T1 (https=) |
| AU (1) | AU2004273610B2 (https=) |
| CA (1) | CA2539741A1 (https=) |
| CY (1) | CY1111246T1 (https=) |
| DE (1) | DE602004018338D1 (https=) |
| DK (1) | DK1663185T3 (https=) |
| ES (1) | ES2317029T3 (https=) |
| NZ (1) | NZ546062A (https=) |
| PL (1) | PL1663185T3 (https=) |
| PT (1) | PT1663185E (https=) |
| SI (1) | SI1663185T1 (https=) |
| WO (1) | WO2005027882A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005279845A1 (en) * | 2004-08-30 | 2006-03-09 | Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Inhibition of viruses using RNase H inhibitors |
| EP1866298A2 (en) | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| DE102005026231A1 (de) * | 2005-06-07 | 2006-12-14 | Origenis Ag | Peptid-Deformylase (PDF) Inhibitoren 3 |
| PL1864668T3 (pl) * | 2006-06-01 | 2013-04-30 | Santen Sas | Wykorzystanie proleku do okulistycznego podawania śródszklistkowego |
| CA2655675A1 (en) | 2006-07-06 | 2008-01-10 | Glaxo Group Limited | Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| KR101022809B1 (ko) * | 2008-02-05 | 2011-03-17 | 재단법인서울대학교산학협력재단 | 면역조절에 의한 캔디다알비칸스 기인성 질환의 치료 |
| JP5637562B2 (ja) * | 2008-09-25 | 2014-12-10 | 塩野義製薬株式会社 | 新規ピロリノン誘導体およびそれを含有する医薬組成物 |
| US20110319416A1 (en) * | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| JP2012041291A (ja) * | 2010-08-18 | 2012-03-01 | Institute Of Physical & Chemical Research | 歯周病の治療または予防剤 |
| ITRM20100614A1 (it) * | 2010-11-24 | 2012-05-25 | D M G Italia S R L | Preparazioni farmaceutiche dell acido 18 beta glicirretico e/o di suoi derivati per infiltrazioni intrarticolari per il trattamento delle artropatie infiammatorie |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| EP2855483B1 (en) | 2012-05-24 | 2017-10-25 | Novartis AG | Pyrrolopyrrolidinone compounds |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
| US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
| MX2015016344A (es) | 2013-05-27 | 2016-03-01 | Novartis Ag | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. |
| US9714249B2 (en) | 2013-05-28 | 2017-07-25 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease |
| CA2912986A1 (en) | 2013-05-28 | 2014-12-04 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease |
| US9550796B2 (en) | 2013-11-21 | 2017-01-24 | Novartis Ag | Pyrrolopyrrolone derivatives and their use as BET inhibitors |
| CN104873520A (zh) * | 2014-02-27 | 2015-09-02 | 天津药物研究院 | 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其用途 |
| CN104873521A (zh) * | 2014-02-27 | 2015-09-02 | 天津药物研究院 | 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其应用 |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| CN118440135A (zh) * | 2017-08-04 | 2024-08-06 | 阿德利克斯股份有限公司 | 用于治疗高钾血症的甘草次酸衍生物 |
| GB201805100D0 (en) * | 2018-03-28 | 2018-05-09 | Benevolentai Bio Ltd | Treatment of sarcopenic diseases |
| KR20260004570A (ko) | 2019-02-07 | 2026-01-08 | 알데릭스, 인코포레이티드 | 고칼륨혈증 치료에 사용하기 위한 글리시레틴산 유도체 |
| WO2025026525A1 (de) * | 2023-07-28 | 2025-02-06 | Symrise Ag | Heterozyklische verbindungen als physiologische kühlstoffe |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3262851A (en) * | 1958-06-26 | 1966-07-26 | Biorex Laboratories Ltd | Pharmacological compositions containing glycyrrhetinic acid derivative |
| DE2050072C3 (de) * | 1970-10-12 | 1975-01-30 | Inverni Della Beffa S.P.A., Mailand (Italien) | Aluminium-tri-3-acetyl-18 betaglycyrrthetinat, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zubereitungen |
| US3934027A (en) * | 1973-05-03 | 1976-01-20 | Pfizer Inc. | 18β-Glycyrrhetinic acid amides useful as antiulcer agents |
| EP0496520A1 (en) * | 1991-01-22 | 1992-07-29 | Merck & Co. Inc. | Novel bone acting agents |
| GB2261672A (en) * | 1991-11-18 | 1993-05-26 | Michael Braden | The use of biomaterials for tissue repair |
| JPH07291857A (ja) * | 1994-04-27 | 1995-11-07 | Suntory Ltd | グリチルレチン酸化合物を有効成分とする骨疾患の予防及び治療剤 |
| DE19951970A1 (de) * | 1999-10-28 | 2001-05-03 | Bionetworks Gmbh | Arzneimittel für die Toleranzinduktion |
| US20050048007A1 (en) * | 2000-11-02 | 2005-03-03 | Inobys Ltd. | Plaque reducing composition |
| GB0105772D0 (en) * | 2001-03-08 | 2001-04-25 | Sterix Ltd | Use |
| GB0107383D0 (en) * | 2001-03-23 | 2001-05-16 | Univ Edinburgh | Lipid profile modulation |
| AU2002353718B2 (en) | 2001-11-22 | 2007-05-10 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| WO2003044000A1 (en) | 2001-11-22 | 2003-05-30 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| WO2003065983A2 (en) | 2002-02-01 | 2003-08-14 | Merck & Co., Inc. | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| EP1546183A4 (en) | 2002-09-23 | 2008-06-18 | Du Pont | ISOLATION AND USE OF RYANODINE RECEPTORS |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| US20030148349A1 (en) * | 2003-01-03 | 2003-08-07 | Shyam Ramakrishnan | Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
-
2004
- 2004-09-21 SI SI200431023T patent/SI1663185T1/sl unknown
- 2004-09-21 AT AT04765458T patent/ATE416761T1/de active
- 2004-09-21 EP EP04765458A patent/EP1663185B1/en not_active Expired - Lifetime
- 2004-09-21 NZ NZ546062A patent/NZ546062A/en unknown
- 2004-09-21 JP JP2006527336A patent/JP2007533625A/ja active Pending
- 2004-09-21 PT PT04765458T patent/PT1663185E/pt unknown
- 2004-09-21 DE DE602004018338T patent/DE602004018338D1/de not_active Expired - Lifetime
- 2004-09-21 ES ES04765458T patent/ES2317029T3/es not_active Expired - Lifetime
- 2004-09-21 AU AU2004273610A patent/AU2004273610B2/en not_active Ceased
- 2004-09-21 CA CA002539741A patent/CA2539741A1/en not_active Abandoned
- 2004-09-21 PL PL04765458T patent/PL1663185T3/pl unknown
- 2004-09-21 DK DK04765458T patent/DK1663185T3/da active
- 2004-09-21 EP EP08169750A patent/EP2036548A1/en not_active Withdrawn
- 2004-09-21 WO PCT/EP2004/010582 patent/WO2005027882A1/en not_active Ceased
- 2004-09-21 US US10/572,795 patent/US20100087413A1/en not_active Abandoned
-
2009
- 2009-03-06 CY CY20091100259T patent/CY1111246T1/el unknown
-
2011
- 2011-05-11 US US13/105,434 patent/US20110275584A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007533625A5 (https=) | ||
| US20220401529A1 (en) | Treatment of diseases involving mucin | |
| JP2009102342A5 (https=) | ||
| MX356032B (es) | Compuestos indola y métodos para tratar el dolor visceral. | |
| JP2016516813A (ja) | 抗菌性シデロフォア−アミノペニシリン複合体 | |
| EP2124930B1 (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders | |
| US20250074907A1 (en) | Inhibitors of sars-cov-2 | |
| EP2037903A1 (en) | Combination methods of treating cancer | |
| CA2600773C (en) | Benzamidine derivatives for treatment and prevention of cancer therapy induced mucositis | |
| EP4335509A3 (en) | Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases | |
| CN1241573C (zh) | 含有丙烯酰司他霉素衍生物以及拓扑异构酶ⅰ和ⅱ抑制剂的药物组合物 | |
| CA2643400A1 (en) | Camptothecin derivatives and their uses | |
| WO2011152721A1 (en) | Derivatives of pantothenic acid and their use for the treatment of malaria | |
| CA2949328A1 (en) | Low substituted polymyxins and compositions thereof | |
| US20080293648A1 (en) | Compositions and Methods for Cancer Treatment | |
| JP2010500971A5 (https=) | ||
| US20220411409A1 (en) | Prodrugs, analogs or derivatives of anthocyanidin as antiviral agents | |
| HK1211213B (en) | Treatment of diseases involving mucin | |
| CN101035545A (zh) | 抗血栓化合物的肺部给药 | |
| JP2005534666A5 (https=) | ||
| HK1095285B (en) | Benzamidine derivatives for treatment and prevention of mucositis | |
| JP2008516958A5 (https=) | ||
| RU2009102229A (ru) | Производные камптотецина с противоопухолевой активностью | |
| HK1058623B (en) | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer | |
| HK1058623A1 (en) | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer |